ENDRA盘中上涨伴随旧Q2业绩和Noble Africa合并进展再传播

ENDRA Life Sciences Inc. (NDRA), a medical technology company developing thermoacoustic biomarker imaging for steatotic liver disease, recently reported second-quarter 2026 financial results and provided an update on its proposed merger with Noble Africa.
The company is developing Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to assess liver fat content and monitor tissue ablation during minimally invasive procedures.
Q2 Financial Readout:
For the second quarter of 2026, ENDRA reported net income of approximately $160,000, compared with a net loss of approximately $1.2 million in the same period of 2025.
Total operating expenses increased to approximately $1.5 million from $1.3 million a year earlier.
The expenses included approximately $542,000 in non-cash stock-based compensation, compared with $89,000 in the prior-year period.
Research and development expenses decreased 39% year over year, while sales and marketing expenses declined 92%.
Cash used in operations during the quarter was approximately $0.9 million, compared with approximately $1.1 million in the second quarter of 2025.
Other income was approximately $1.6 million, primarily reflecting realized and unrealized gains associated with ENDRA's digital asset treasury.
As of June 30, 2026, ENDRA had approximately $1.7 million in cash, $3.8 million in restricted cash and $1.9 million in its Digital Asset Treasury.
Noble Africa Merger:
On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc., Noble Africa LLC and Renergen Limited.
Under the agreement, Noble Africa will merge with a wholly owned subsidiary of ENDRA and become its wholly owned subsidiary.
Following completion of the transaction, ENDRA is expected to be renamed Noble Africa Inc.
The proposed merger is intended to provide ENDRA stockholders with exposure to Renergen's Virginia Gas Project in South Africa.
In connection with the transaction, Noble Africa entered into subscription agreements for a private placement expected to generate approximately $50 million in gross proceeds.
The merger is currently expected to close in the fourth quarter of 2026, subject to customary closing conditions, including stockholder and regulatory approvals.
ENDRA also completed a $3.8 million private placement on May 28, 2026, with the proceeds classified as restricted cash as of June 30.
ENDRA said it is working with ASP Isotopes, Renergen and Noble Africa to satisfy the conditions required to complete the proposed merger.
Currently, NDRA is trading at $6.37, up 12.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 28, 2026 14:11 ET Consumer prices data and economic output figures were the main news on the economics front in the U.S. this week. Similarly, latest data on demand for durable goods also drew attention. Survey data on the business morale in the biggest euro economy, Germany, were in focus in Europe. In Asia, the interest rate announcement from South Korea was the highlight.